Cerenome, Inc.

CNSY Healthcare Biotechnology

Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.70 0.18 −9.57%
Market cap
$14.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
3/9
Altman Z
−44.87
Beneish M
−3.46
Dividend safety
n/a

Cerenome, Inc. (CNSY) P/E ratio

Alert me on P/E ratio

Cerenome, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.8× (August 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —
FY2015 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
34 more quarters

Against its own ten years

Low 0.0× High 6.8×
Ten-year median 0.0×
Current reading's percentile 96

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CNSY